Bladder, prostate, kidney and testis represent significant challenges to the anatomic diagnostician because recent advances in molecular medicine have created a shift in classification, treatment and prognosis, altering and augmenting the visual interpretation of their morphology. Whether you are in academic or community practice, an experienced pathologist or a trainee, the opportunity to review challenging cases with established experts in urologic pathology ignites the mental algorithms leading to precise diagnoses. Target Audience
General surgical pathologists, urological pathologists, pathology residents and fellows. Learning Objectives
Upon completion of this educational activity, learners will be able to:
- Recognize the most common benign mimickers of prostate cancer, identify therapy related changes in the prostate and be aware of potential diagnostic pitfalls.
- Identify secondary tumors involving the prostate, tumors arising from the prostatic urethra and histologic variants of prostate cancer.
- Update pathologists on newly described entities in renal neoplasia, including diagnostic guidelines for using immunohistochemistry in the work-up of renal tumors.
- Discuss various aspects of reporting RCC, including grading and staging, and also discuss the work-up of needle biopsy of renal tumors.
- Develop a systematic approach to the diagnosis of bladder lesions, primary and secondary bladder tumors, and benign mimickers of malignancy, and also staging criteria.
- Introduce the new concepts and entities presented in WHO 2016 classification, including up to date information on diagnosis, clinical behavior and management.
- Present different challenging diagnostic entities with relevant discussions including differential diagnosis, morphologic mimics and prognostic significance.
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 12 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The USCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABPath requirements for Continuing Certification (CC). Registrants must take and pass the post-test in order to claim SAMs credit.
Physicians can earn a maximum of 12 SAM credit hours.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported no relevant financial relationships: Muhammad T. Idrees M.D., M.B.B.S., Cristina Magi-Galluzzi, M.D., Ph.D., Adeboye O. Osunkoya, M.D., Ming Zhou, M.D., Ph.D.
USCAP staff associated with the development of content for this activity reported no relevant financial relationships. To earn CME and SAM credit, all learners must take a content-based exam and achieve a minimum score of 80%. If learners do not achieve a passing score of 80%, they have the option to retake the exam. After you pass the test and complete the evaluation, your certificate of completion will be available to view and print by clicking here.